Company profile
Anaveon AG
We are developing IL-2 complexes which selectively promote effector T cell functions. Our compounds act as effective immune adjuvants with a broad therapeutic window and marked preclinical efficacy against cancer either as monotherapy or in combination with other therapies.
Source: startup.ch
Highlights
Top 100 Swiss Startup Award 2022
Top 100 Swiss Startup Award 2020
Top 100 Swiss Startup Award 2019
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
